|
See related Aclasta infusion information |
|
|
|
Manufacturer |
Novartis |
|
Distributor |
Hong Kong: Zuellig/Macau: Four Star |
|
Contents |
Zoledronic acid |
|
Indications |
Treatment of osteoporosis in postmenopausal women & in men. Prevention of clinical fractures after hip fracture. Treatment & prevention of glucocorticoid-induced osteoporosis. Paget's bone disease.
Click to view Aclasta detailed prescribing infomation |
|
Dosage |
Osteoporosis 5 mg once a yr as a single 15-min IV infusion. Paget's bone disease 5 mg as a single 15-min IV infusion. Supplement w/ Ca 1,000 mg/day & a daily dose of vit D during the 1st 10 days folllowing administration of Aclasta. Hip fracture Oral or IM dose of vit D3 50,000-125,000 IU prior to infusion of Aclasta.
Click to view Aclasta detailed prescribing infomation |
|
Overdosage |
View Aclasta overdosage for action to be taken in the event of an overdose. |
|
Contraindications |
Hypocalcemia. Pregnancy & lactation.
Click to view Aclasta detailed prescribing infomation |
|
Special Precautions |
Treat preexisting hypocalcemia & mineral metabolism disturbances prior to use. Monitor serum creatinine. Ensure adequate hydration prior to administration esp during diuretic therapy. Severe renal impairment. Potential osteonecrosis of the jaw (ONJ) in cancer patients treated w/ biphosphonates. Avoid invasive dental procedures in patients w/ concomitant risk factors (cancer, chemotherapy, corticosteroids, poor oral hygiene). Childn & adolescents <18 yr.
Click to view Aclasta detailed prescribing infomation |
|
Adverse Drug Reactions |
Fever, myalgia, flu-like symptoms, arthralgia; headache, dizziness, nausea, vomiting, diarrhoea, night sweats, bone & back pain, pain in the extremities, chills, fatigue, asthenia, inj-site pain, malaise.
View ADR Monitoring Form |
|
Drug Interactions |
Nephrotoxic drugs.
View more drug interactions with Aclasta |
|
Pregnancy Category (US FDA) |
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective). |
|
Caution For Usage |
For caution against possible variation of physical aspect of medicine... click to view Aclasta detailed prescribing infomation |
|
Storage |
View Aclasta storage conditions for details to ensure optimal shelf-life. |
|
Description |
View Aclasta description for details of the chemical structure and excipients (inactive components). |
|
Mechanism of Action |
View Aclasta mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
